DAREHealthcare · BiotechnologyThe 3 Wall Street analysts covering Daré Bioscience, Inc. hold a median 12-month price target of $5 — +672.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 13 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Daré Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (89): Smaller than most of the companies we track.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on DARE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +672.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Oct 2026 | Ladenburg Thalmann | Assumes | Buy | $2.00 |
| 2 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 2 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Sept 2025 | Maxim Group | Upgrade | Buy | — |
| 1 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Aug 2024 | Jones Trading | Maintains | Buy | — |
| 14 Aug 2024 | Maxim Group | Downgrade | Hold | — |
| 15 May 2024 | Brookline Capital | Upgrade | Buy | — |
| 15 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Apr 2024 | Brookline Capital | Downgrade | Hold | — |
| 1 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 July 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DARE appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Nov 2026, Daré Bioscience, Inc. returned −65.8% against +13.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 14% of US stocks
Cheaper than 98% of US stocks
Cheaper than 67% of US stocks
Higher than 72% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 6% of US stocks
Higher than 98% of US stocks
Higher than 3% of US stocks
Higher than 11% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Daré Bioscience, Inc. has a market value of $12.7M and an enterprise value of $4.0M.
Revenue in the twelve months to 30 June 2026: $1.4M. The latest quarter grew 23.0% year on year.
Net income over the same four quarters: −$11.0M, a −804.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$11.8M.
Trailing P/E: 0.1×; forward P/E: −1.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Daré Bioscience, Inc. employs 21 people — $65K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Daré Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Daré Bioscience announced a conference call and webcast for 4:30 p.m. Eastern Time on November 16, 2026, to review financial results for the quarter ended September 30 and provide a company update.
Why it matters — DARE watchers can use the scheduled event to hear the company’s quarterly results and update directly.
Daré Bioscience released a new episode of its “CEO Corner” video series. Founder, President and CEO Sabrina Martucci Johnson discusses potential value drivers for the company’s next phase of growth and commercial success.
Why it matters — The episode outlines management’s perspective on potential drivers of Daré’s growth and commercial plans.
Daré Bioscience announced that CEO Sabrina Martucci Johnson is scheduled to present at Stifel’s 2026 Healthcare Conference, taking place November 10–12 in New York City.
Why it matters — The presentation gives DARE watchers a scheduled opportunity to hear from the company’s CEO at an upcoming healthcare conference.
Daré Bioscience said its non-dilutive grant funding has surpassed $43 million, including a latest $1.5 million installment. The funding reflects continued milestone progress as DARE-LARC1 advances in preclinical development.
Why it matters — The funding total and DARE-LARC1’s development progress are updates on the company’s investigational drug-delivery platform.
Daré Bioscience CEO Sabrina Martucci Johnson discussed a recent White House Executive Order in a virtual investor conversation, describing how the company’s commercial portfolio and clinical pipeline relate to unmet needs in women’s health.
Why it matters — The discussion provides a company perspective on how Daré’s portfolio and pipeline align with renewed national attention to women’s health.
The 3 Wall Street analysts covering Daré Bioscience, Inc. have a median 12-month price target of $5, with estimates ranging from $2 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Daré Bioscience, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Daré Bioscience, Inc. 27 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, Daré Bioscience, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +672.9% from the last close, and Ticker Nerd's factor model ranks Daré Bioscience, Inc. 27 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Daré Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DARE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $12 over the next 12 months.
Daré Bioscience, Inc. returned -65.8% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on women’s health.
The most recent item we track (GlobeNewsWire, 10 Nov 2026): "Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026". Daré Bioscience announced a conference call and webcast for 4:30 p.m. Eastern Time on November 16, 2026, to review financial results for the quarter ended September 30 and provide a company update.
Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on women’s health. Daré Bioscience develops and commercializes therapies in contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health, with an emphasis on improving treatment options and convenience for women. Its portfolio includes approved and investigational products designed to address unmet needs in reproductive and intimate health, such as non-hormonal contraception, vaginal health treatments, and hormone-related therapies. The company operates as a product-driven biotech business, advancing candidates through clinical development and regulatory pathways in the United States. Headquartered in San Diego, California, Daré Bioscience plays a specialized role in the healthcare market by concentrating on differentiated solutions for areas that are often underrepresented in women’s medicine.
CEO Ms. Sabrina Martucci Johnson · 21 employees · United States · https://darebioscience.com
